The Apoptotic Effect of Cordycepin on Human OEC-M1 Oral Cancer Cell Line
Overview
Affiliations
Cordycepin (3'-deoxyadenosine), a pure compound of Cordyceps sinensis, has been illustrated with anti-tumor effects. In the present study, the apoptotic effect of cordycepin on OEC-M1, a human oral squamous cancer cell line, was investigated by morphological observations, cell viability assay, annexin V-FITC analysis and flow cytometry methods. Results demonstrated that the number of rounded-up cell increased as treatment duration of cordycepin (100 microM) increased from 3 to 48 h, and the plasma membrane blebbing could be observed after 12 h treatment. In cell viability assay, cell surviving rate significantly decreased as the dosage and duration of cordycepin treatment increased (P < 0.05). Moreover, phosphatidylserine flipping on cell membrane could be detected with 3, 6 and 12 h cordycepin treatment, which indicated an early apoptotic phenomenon. Furthermore, cell cycle studies illustrated that the percentage of G1 phase cell declined as the dosages of cordycepin increased (10 microM to 5 mM), while the percentages of G2M and subG1 phase cell increased (P < 0.05) in 12, 24 and 48 h cordycepin treatment. These results further confirmed the apoptotic event. In conclusion, cordycepin significantly induced cell apoptotsis in OEC-M1 human oral squamous cancer cells.
-Derived Bioactive Gels: Therapeutic and Anti-Aging Applications in Dermatology.
Nguyen T, Van Pham T, Andriana Y, Truong M Gels. 2025; 11(1).
PMID: 39852004 PMC: 11764995. DOI: 10.3390/gels11010033.
Cordycepin enhances anti-tumor immunity in breast cancer by enhanceing ALB expression.
Chen L, Wei W, Sun J, Sun B, Deng R Heliyon. 2024; 10(9):e29903.
PMID: 38720766 PMC: 11076851. DOI: 10.1016/j.heliyon.2024.e29903.
Application of Natural Medicinal Plants Active Ingredients in Oral Squamous Cell Carcinoma.
Ren Q, Li X, Tian T, Li S, Shi R, Wang Q Chin J Integr Med. 2024; 30(9):852-864.
PMID: 38607612 DOI: 10.1007/s11655-024-3804-7.
Tung K, Wu S, Yang C, Chang H, Chang C, Wang Y Evid Based Complement Alternat Med. 2023; 2022:1842363.
PMID: 38023774 PMC: 10667060. DOI: 10.1155/2022/1842363.
Binlateh T, Uppatcha N, Thepchai J, Pleungtuk Y, Noisa P, Hutamekalin P J Dent Sci. 2022; 17(4):1677-1688.
PMID: 36299321 PMC: 9588793. DOI: 10.1016/j.jds.2022.03.002.